seri
substitut
analog
cnucleosid
prepar
evalu
potenti
antivir
agent
compound
show
broad
rang
inhibitori
activ
variou
rna
virus
particular
whole
cell
potenc
hcv
r
cn
attribut
inhibit
hcv
polymeras
intracellular
concentr
correspond
nucleosid
triphosph
elsevi
ltd
right
reserv
structur
modif
natur
nnucleosid
either
sugar
base
led
discoveri
varieti
therapeut
agent
includ
antivir
anticanc
agent
approach
continu
employ
identifi
agent
improv
efficaci
safeti
exist
drug
overcom
issu
associ
drugresist
expand
new
therapeut
area
among
conceiv
modif
sugar
moieti
incorpor
substitut
posit
nnucleosid
rare
exploit
drug
discoveri
partli
due
chemic
instabl
induc
substitu
ie
readi
dissoci
base
sugar
lower
ph
exampl
cme
adenosin
rapidli
degrad
aqueou
solut
ph
howev
cnucleosid
sugar
base
link
cc
bond
hydrolyt
stabl
even
substitu
thu
envis
cnucleosid
could
ideal
scaffold
explor
variou
substitut
nucleosid
therapeut
potenti
part
ongo
effort
identifi
new
antivir
agent
interest
investig
substiut
nucleosid
inhibitor
viral
rnadepend
rna
polymeras
nucleosid
inhibitor
convert
intracellular
kinas
triphosphoryl
nucleosid
function
competitor
natur
nucleosid
triphosph
tp
rna
synthesi
tubercidin
natur
occur
cytotox
nnucleosid
triphosphoryl
insid
cell
incorpor
rna
host
rna
polymeras
believ
main
mode
action
observ
cytotox
cnucleosid
analog
shown
equal
potent
cytotox
cancer
cell
line
tp
also
shown
substrat
host
rna
polymeras
incorpor
rna
unpublish
result
thu
chose
compound
templat
investig
effect
substitu
antivir
activ
select
report
prepar
seri
novel
substitut
analog
compound
antivir
activ
panel
rna
virus
correl
observ
antihcv
potenc
intrins
enzym
hcv
activ
intracellular
level
correspond
tp
ho
ho
n
n
n
nh
oh
ho
ho
n
n
n
nh
oh
compound
prepar
common
intermedi
obtain
coupl
bromo
heterocycl
ribonolacton
scheme
result
hemiket
react
tmscn
alm
presenc
bf
et
afford
compound
r
cn
r
respect
vinyl
magnesium
bromid
ethynyl
magnesium
chlorid
follow
dehydr
ring
closur
methanesulfon
acid
provid
compound
r
vinyl
r
ethynyl
respect
product
obtain
mixtur
see
front
matter
seri
substitut
analog
cnucleosid
prepar
evalu
potenti
antivir
agent
compound
show
broad
rang
inhibitori
activ
variou
rna
virus
particular
whole
cell
potenc
hcv
r
cn
attribut
inhibit
hcv
polymeras
intracellular
concentr
correspond
nucleosid
triphosph
elsevi
ltd
right
reserv
structur
modif
natur
nnucleosid
either
sugar
base
led
discoveri
varieti
therapeut
agent
includ
antivir
anticanc
agent
approach
continu
employ
identifi
agent
improv
efficaci
safeti
exist
drug
overcom
issu
associ
drugresist
expand
new
therapeut
area
among
conceiv
modif
sugar
moieti
incorpor
substitut
posit
nnucleosid
rare
exploit
drug
discoveri
partli
due
chemic
instabl
induc
substitu
ie
readi
dissoci
base
sugar
lower
ph
exampl
cme
adenosin
rapidli
degrad
aqueou
solut
ph
howev
cnucleosid
sugar
base
link
cc
bond
hydrolyt
stabl
even
substitu
thu
envis
cnucleosid
could
ideal
scaffold
explor
variou
substitut
nucleosid
therapeut
potenti
part
ongo
effort
identifi
new
antivir
agent
interest
investig
substiut
nucleosid
inhibitor
viral
rnadepend
rna
polymeras
nucleosid
inhibitor
convert
intracellular
kinas
triphosphoryl
nucleosid
function
competitor
natur
nucleosid
triphosph
tp
rna
synthesi
tubercidin
natur
occur
cytotox
nnucleosid
triphosphoryl
insid
cell
incorpor
rna
host
rna
polymeras
believ
main
mode
action
observ
cytotox
cnucleosid
analog
shown
equal
potent
cytotox
cancer
cell
line
tp
also
shown
substrat
host
rna
polymeras
incorpor
rna
unpublish
result
thu
chose
compound
templat
investig
effect
substitu
antivir
activ
select
report
compound
prepar
common
intermedi
obtain
coupl
bromo
heterocycl
ribonolacton
scheme
result
hemiket
react
tmscn
alm
presenc
bf
et
afford
compound
r
cn
r
respect
vinyl
magnesium
bromid
ethynyl
magnesium
chlorid
follow
dehydr
ring
closur
methanesulfon
acid
provid
compound
r
vinyl
r
ethynyl
respect
product
obtain
mixtur
two
stereoisom
posit
subsequ
debenzyl
use
bcl
provid
chromatograph
separ
two
isom
desir
nucleosid
addit
tp
deriv
bi
sate
monophosph
prodrug
cnucleosid
also
prepar
accord
publish
method
synthes
nucleosid
evalu
cellbas
assay
panel
rna
virus
antihcv
activ
obtain
use
subgenom
replicon
virus
test
includ
repres
flavivirida
hcv
yfv
wnv
orthomyxovirida
influenza
paramyxovirida
parainfluenza
picornavirida
coxsacki
coronavirida
sarscov
antivir
activ
ec
cytotox
cc
host
cell
assay
shown
tabl
compound
r
cn
display
broader
spectrum
activ
hcv
yfv
influenza
parainfluenza
sarscov
compound
show
reduc
potenc
narrow
spectrum
antivir
activ
activ
exhibit
variou
level
antivir
activ
substitut
nucleosid
exert
littl
cytotox
investig
see
observ
antivir
activ
deriv
inhibit
viral
rna
depend
rna
polymeras
rdrp
sinc
readili
avail
hcv
rdrp
use
determin
enzym
inhibitori
activ
tp
establish
protocol
ic
valu
obtain
tabl
studi
reveal
good
correl
intrins
enzym
activ
whole
cell
hcv
potenc
exampl
compound
show
potent
antihcv
activ
ec
lm
tp
deriv
potent
inhibitori
activ
enzym
ic
lm
gain
insight
mode
antivir
activ
bi
sate
monophosph
prodrug
test
hcv
replicon
assay
addit
intracellular
level
tp
measur
upon
incub
prodrug
replicon
cell
compar
parent
nucleosid
result
summar
tabl
prodrug
show
markedli
enhanc
replicon
activ
compar
parent
nucleosid
monophosph
prodrug
afford
higher
level
tp
speci
parent
nucleosid
correspond
increas
potenc
increas
cytotox
also
observ
prepar
prodrug
select
indic
cc
ec
less
make
difficult
differenti
hcv
activ
cellular
toxic
greater
potenc
select
observ
ec
lm
select
like
reflect
combin
potent
enzym
activ
high
intracellular
tp
concentr
pmolmillion
cell
cell
incub
lm
structur
modif
improv
select
warrant
summari
seri
novel
substitut
analog
cnucleosid
prepar
test
vitro
antivir
assay
compound
show
broad
rang
antivir
activ
particular
hcv
potenc
bi
sate
prodrug
whole
cell
replicon
assay
correl
intrins
enzym
activ
intracellular
level
correspond
tp
suggest
antivir
activ
part
deriv
inhibit
rdrp
current
work
establish
potenti
substitut
nucleosid
antivir
agent
cold
sodium
chlorid
salin
cell
scrape
ml
methanol
frozen
overnight
facilit
extract
nucleotid
metabolit
extract
cell
materi
methanol
transfer
tube
dri
dri
sampl
resuspend
mm
ammonium
phosphat
ph
tp
level
quantit
use
liquid
chromatographi
coupl
tripl
quadrapol
mass
spectrometri
method
similar
previous
report
durand
c
max
intracellular
tp
pmolmillion
cell
upon
incub
lm
nucleosid
prodrug
cell
h
